Larimar Therapeutics Nomlabofusp Protein Replacement Therapy for Friedreich's Ataxia Webinar

This video is a recording of an informational webinar hosted by Larimar Therapeutics on November 4, 2024. Rusty Clayton, DO, Chief Medical Officer, at Larimar Therapeutics provided an update on the nomlabofusp program. Nomlabofusp is an investigational recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with Friedreich’s ataxia (FA), and it is under evaluation and not approved by the FDA as of the date of this recording. This video recording is being made available without the question and answer portion of the webinar. Information shared in this webinar is for educational purposes only and should not be construed as medical advice. FARA makes no representations regarding the information included in the recording.

Those viewing the recording after November 4, 2024, are reminded that the field is constantly evolving and the information contained in this recording may have changed. Anyone considering participating in a clinical trial should discuss the matter with their physician. FARA does not endorse or recommend any particular study.

About FARA:
FARA's Mission is to marshal and focus the resources and relationships needed to cure Friedreich's Ataxia (FA) by raising funds for research, promoting public awareness, and aligning scientists, patients, clinicians, government agencies, pharmaceutical companies and other organizations dedicated to curing FA and related diseases.

Friedreich’s Ataxia is a debilitating, life-shortening, degenerative neuro-muscular disorder. About one in 50,000 people in the United States have Friedreich's Ataxia.

Subscribe to FARA's YouTube channel https://www.youtube.com/user/FARA1998
Follow FARA on Facebook https://www.facebook.com/CureFA/
Follow FARA on Instagram https://www.instagram.com/curefa_org/